BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) Reagent for use in diagnostics and/or therapy, characterised in that, ~~at~~ in at least two spatially separated positions on a cell-bound or soluble molecule, it enters into interactions with the latter or the nucleic acid coding for this.

2. (original) Reagent according to Claim 1, characterised in that it covers at least one antigen binding domain.

3. (currently amended) Reagent according to one of the claim ~~Claims~~ 1 ~~or 2~~, characterised in that it is selected from antibodies, antibody fragments, chimerized antibodies, humanised antibodies, single chain (sc)Fv fragments, scT-cell receptor (TCR) fragments, hybrid scFv/scTCR fragments, RNA or DNA aptamers and RNA or DNA Spiegelmers.

4. (currently amended) Reagent according to one of the claim ~~Claims~~ 1 ~~to 3~~, characterised in that it binds to CD30.

5. (currently amended) Reagent according to one of the claim ~~Claims~~ 1~~to 4~~, characterised in that it binds to an epitope with the core sequence CEPDY.

6. (currently amended) Reagent according to one of the claim ~~Claims~~ 1~~to 5~~, characterised in that the reagent is a chimerized antibody or a fragment of the same.

7. (currently amended) Reagent according to one of the claim ~~Claims~~ 1~~to 6~~, characterised in that the reagent is available from a culture medium of the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548.

8. (currently amended) Reagent according to one of the claim ~~Claims~~ 1 ~~to 7~~, characterised in that it also contains a toxin and/or a marking.

9. (original) Reagent according to Claim 8, characterised in that it is linked peptidically or via linker molecules with toxic proteins or with enzymes or proenzymes.

10. (original) Reagent according to Claim 9, characterised in that it is linked with toxins in the form of ribosome-inactivating proteins.

11. (original) Reagent according to Claim 9, characterised in that it is linked with enzymes from the group of the phosphodiesterases.

12. (original) Reagent according to Claim 9, characterised in that it is linked directly or via a linker molecule covalently or conjugated with radioactive isotopes.

13. (original) Reagent according to Claim 12, characterised in that the radioactive isotopes are selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. (currently amended) Reagent according to claim ~~Claims~~ 8 ~~to 9~~, characterised in that it is linked directly or via linker molecules covalently or conjugated with photactivatable compounds.

15. (currently amended) Cell which produces a reagent according to ~~one of the Claims~~ claim 1 ~~to 7~~.

16. (original) Cell according to Claim 15, characterised in that it contains a recombinant DNA which codes for the reagent or a part thereof.

17. (currently amended) Cell according to claim ~~one of the Claims~~ 15 ~~or 16~~, characterised in that it shows essential features of the cell as stored at the DSM under no. DSM ACC2548, especially the ability to give off the antibody in a considerably higher concentration into the medium than comparable cells.

18. (currently amended) Cell according to claim ~~one of the Claims~~ 15 ~~or 16~~, characterised in that it was stored at the DSM under the no. DSM ACC2548.

19. (currently amended) Method for the diagnosis especially of tumours and inflammatory diseases, characterised in that a sample from the test person is brought into contact with a reagent according to claim ~~one of the Claims 1 to 14~~ and the extent of the reaction of the reagent with the sample is determined.

20. (original) Method for the diagnosis of diseases, characterised in that the diagnosis is carried out in vivo and that it covers, for example, a scintigraphy.

21. (currently amended) ~~Use of a reagent according to one of the Claims 1 to 14 for the treatment of~~ A method of treating a patient having tumours, inflammatory, inflammatory-allergic and/or autoimmune diseases, comprising dispensing a reagent according to claim 1.

22. (currently amended) The method ~~Use~~ according to Claim 21, characterised in that the tumour is a lymphoma or embryonal carcinoma.

23. (currently amended) The method ~~Use~~ according to Claim 22, characterised in that the lymphoma is a CD30-positive lymphoma.

24. (currently amended) The method ~~Use~~ according to Claim 23, characterised in that the CD30-positive lymphoma is a Hodgkin's lymphoma, an anaplastic large-cell lymphoma or an acute or lymphomatous form of adult T-cell leukaemia.

25. (currently amended) The method ~~Use~~ according to ~~one of the Claims~~ claim 21 ~~to 24~~, characterised in that 10 to 1000 mg/m^2 body surface of reagent is dispensed.

26. (currently amended) The method ~~Use~~ according to Claim 25, characterised in that 20 to 400 mg/m^2 body surface of reagent is dispensed.

27. (currently amended) The method ~~Use~~ according to claim ~~one of the Claims~~ 21 ~~to 26~~, characterised in that the reagent is dispensed i.v.

28. (currently amended) ~~Use of a reagent according to one of the Claims 1 to 14 for the production of~~ A method of making a composition for the suppression or avoidance of a

rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells comprising incorporating a reagent according to claim 1 into a composition.

29. (currently amended) Pharmaceutical composition containing a reagent according to claim ~~one of the Claims~~ 1 ~~to 14~~.

30. (currently amended) Kit for the diagnosis in particular of tumours, especially CD30-positive neoplasies, and inflammatory diseases, containing a reagent according to ~~one of the Claims~~ claim 1 ~~to 14~~ together with instructions for use for the reagent.